18/04/2019 15:11:46

CLASS ACTION UPDATE for CORT, AVEO, DPLO and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Corcept Therapeutics Incorporated (NASDAQCM: CORT)

Class Period: August 2, 2017 - February 5, 2019

Lead Plaintiff Deadline: May 13, 2019

Join the action: https://www.zlk.com/pslra-1/corcept-therapeutics-incorporated-loss-form?wire=3

The lawsuit alleges: Corcept Therapeutics Incorporated made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the Company had improperly paid doctors to promote its drug Korlym; (2) the Company aggressively promoted Korlym for off-label uses; (3) the Company’s sole specialty pharmacy was a related party; (4) the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Corcept Therapeutics Incorporated class action contact jlevi@levikorsinsky.com.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)

Class Period: August 4, 2016 - January 31, 2019

Lead Plaintiff Deadline: April 26, 2019

Join the action: https://www.zlk.com/pslra-1/aveo-pharmaceuticals-inc-loss-form?wire=3

The lawsuit alleges that, during the class period, AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.

To learn more about the AVEO Pharmaceuticals, Inc. class action contact jlevi@levikorsinsky.com.

Diplomat Pharmacy, Inc. (NYSE: DPLO)

Class Period: February 26, 2018 - February 21, 2019

Lead Plaintiff Deadline: April 25, 2019

Join the action: https://www.zlk.com/pslra-1/diplomat-pharmacy-inc-loss-form?wire=3

The lawsuit alleges: Diplomat Pharmacy, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Diplomat Pharmacy, Inc. class action contact jlevi@levikorsinsky.com.

Mobile TeleSystems PJSC (NYSE: MBT)

Class Period: March 19, 2014 - March 7, 2019

Lead Plaintiff Deadline: May 20, 2019

Join the action: https://www.zlk.com/pslra-1/mobile-telesystems-pjsc-loss-form?wire=3

The lawsuit alleges that, during the class period, Mobile TeleSystems PJSC made materially false and/or misleading statements and/or failed to disclose that: (1) MTS and its subsidiary were involved in a scheme to pay $420 million in bribes in Uzbekistan; (2) consequently, MTS knew or should have known it would be forced to pay substantial fines to the U.S. government after disclosing in 2014 that the U.S. Department of Justice and Securities and Exchange Commission were investigating its Uzbekistan operations; (3) MTS’ level of cooperation with the U.S. government and remediation was lacking; (4) due to the aforementioned misconduct, MTS would be forced to pay approximately $850 million in criminal penalties to the U.S. government; and (5) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

To learn more about the Mobile TeleSystems PJSC class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com 

250x148_zlk.jpg

Related content
28 May - 
Corcept Therapeutics to Present Data from Phase 1/2 Tri..
20 May - 
MBT, HCSG & ARA - Bronstein, Gewirtz & Grossman, LLC Cl..
20 May - 
DEADLINE MONDAY: The Schall Law Firm Announces the Fili..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sprint Corporation, Boston Scientific Corporation, Box, Inc. and Cloudera, Inc. and Encourages Investors to Contact the Firm
2
ROHM's New Power Supply Monitoring IC with Built-In Self-Diagnostic Function that Supports Functional Safety
3
Genocea Announces Pricing of $36,750,000 Public Offering of Common Stock
4
Equity Trustees appointed Authorised Corporate Director to the AllianceBernstein UK OEIC
5
Atreca Announces Pricing of Initial Public Offering

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 June 2019 15:09:19
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-20 16:09:19 - 2019-06-20 15:09:19 - 1000 - Website: OKAY